HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.

Abstract
The tyrosine kinase inhibitor STI571 is a novel promising class of anticancer drugs. We report a case of cutaneous adverse reactions to STI571 in a young woman with blast crisis of chronic myeloid leukemia. She had first typical acute generalized exanthematous pustulosis mimicking mercury rash and then urticarial eruption. We suggest that cell pathways mediated by some tyrosine kinases might be involved in the pathogenesis of these skin eruptions.
AuthorsM C Brouard, C Prins, S Mach-Pascual, J H Saurat
JournalDermatology (Basel, Switzerland) (Dermatology) Vol. 203 Issue 1 Pg. 57-9 ( 2001) ISSN: 1018-8665 [Print] Switzerland
PMID11549802 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2001 S. Karger AG, Basel
Chemical References
  • Antineoplastic Agents
  • Benzamides
  • Enzyme Inhibitors
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
Topics
  • Acute Disease
  • Adult
  • Antineoplastic Agents (adverse effects)
  • Benzamides
  • Diagnosis, Differential
  • Drug Eruptions (diagnosis, etiology)
  • Enzyme Inhibitors (adverse effects)
  • Exanthema (chemically induced, diagnosis)
  • Female
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
  • Piperazines (adverse effects)
  • Protein-Tyrosine Kinases (antagonists & inhibitors)
  • Pyrimidines (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: